Telomerase as Drug and Drug Target for the Treatment of Thyroid Cancer

Author(s): M. A. Zeiger, A. K. Meeker

Journal Name: Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Continued as Endocrine, Metabolic & Immune Disorders - Drug Targets

Volume 4 , Issue 3 , 2004


Telomerase is known to be activated in almost all cancer cells and is quiescent in almost all normal cells. Therefore, it follows that therapeutic strategies directed against cancer would include the targeting of telomerase, as well as the use of telomerase. Several approaches have been used both in vitro and in vivo and include the following: 1) antisense; 2) immunotherapy directed against hTERT; and 3) the use of telomerase promoter to direct cytotoxic therapy. Herein we review these approaches and discuss their potential applicability against thyroid cancer.

Keywords: telomerase, thyroid cancer, drug target, immunotherapy, antisense strategy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Published on: 01 March, 2012
Page: [253 - 256]
Pages: 4
DOI: 10.2174/1568005310404030253
Price: $65

Article Metrics

PDF: 1